Shots:
- NGM to receive ~ $120M as research & development funding through Mar’24, including ~$86M for the period from Apr’21 through Mar’22 & additional option payments if Merck exercises license option
- The collaboration will initially focus on retinal and CVM diseases with NGM621 and MK-3655. Merck retains its option to license NGM621, currently being evaluated in the P-III CATALINA study for geographic atrophy
- NGM to get WW rights to its disclosed oncology portfolio including NGM120, NGM707, & NGM438, preclinical, current, and future research, assets falling outside of the amended collaboration’s narrower scope, in exchange to which Merck will receive royalties
Click here to read full press release/ article | Ref: Globe Newswire | Image: NGM Biopharmaceuticals
The post Merck Amends Collaboration with NGM to Advance Novel Therapies for Retinal and CVM Diseases first appeared on PharmaShots.
